Trevi Therapeutics Future Growth
Future criteria checks 0/6
Trevi Therapeutics is forecast to grow earnings and revenue by 42.8% and 70.1% per annum respectively while EPS is expected to grow by 43.6% per annum.
Key information
42.8%
Earnings growth rate
43.64%
EPS growth rate
| Pharmaceuticals earnings growth | 12.8% |
| Revenue growth rate | 70.1% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 02 Jan 2026 |
Recent future growth updates
Recent updates
Trevi Therapeutics: "Buy" Rating For Haduvio Treating Chronic Cough In IPF And Beyond
Dec 03We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth
Apr 02
We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth
Sep 27We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth
May 24Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans
Jan 27Trevi adds 19% on full data set from mid-stage cough study
Sep 19Trevi Therapeutics: Moving Forward
Sep 11Is Trevi Therapeutics (NASDAQ:TRVI) Using Too Much Debt?
Mar 23Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 65 | -69 | -170 | -103 | 9 |
| 12/31/2027 | 3 | -101 | -132 | -130 | 9 |
| 12/31/2026 | N/A | -74 | -95 | -88 | 9 |
| 12/31/2025 | N/A | -50 | -53 | -29 | 9 |
| 9/30/2025 | N/A | -46 | -44 | -44 | N/A |
| 6/30/2025 | N/A | -47 | -43 | -43 | N/A |
| 3/31/2025 | N/A | -47 | -41 | -41 | N/A |
| 12/31/2024 | N/A | -48 | -38 | -38 | N/A |
| 9/30/2024 | N/A | -44 | -35 | -35 | N/A |
| 6/30/2024 | N/A | -39 | -33 | -33 | N/A |
| 3/31/2024 | N/A | -34 | -34 | -34 | N/A |
| 12/31/2023 | N/A | -29 | -32 | -32 | N/A |
| 9/30/2023 | N/A | -27 | -32 | -32 | N/A |
| 6/30/2023 | N/A | -27 | -33 | -33 | N/A |
| 3/31/2023 | N/A | -28 | -29 | -29 | N/A |
| 12/31/2022 | N/A | -29 | -28 | -28 | N/A |
| 9/30/2022 | N/A | -32 | -28 | -28 | N/A |
| 6/30/2022 | N/A | -31 | -27 | -27 | N/A |
| 3/31/2022 | N/A | -33 | -28 | -28 | N/A |
| 12/31/2021 | N/A | -34 | -29 | -29 | N/A |
| 9/30/2021 | N/A | -35 | -32 | -32 | N/A |
| 6/30/2021 | N/A | -35 | -31 | -31 | N/A |
| 3/31/2021 | N/A | -33 | -32 | -32 | N/A |
| 12/31/2020 | N/A | -33 | -29 | -29 | N/A |
| 9/30/2020 | N/A | -30 | -26 | -26 | N/A |
| 6/30/2020 | N/A | -30 | -27 | -27 | N/A |
| 3/31/2020 | N/A | -29 | -24 | -24 | N/A |
| 12/31/2019 | N/A | -27 | -23 | -23 | N/A |
| 9/30/2019 | N/A | -28 | -22 | -22 | N/A |
| 6/30/2019 | N/A | -27 | N/A | -18 | N/A |
| 3/31/2019 | N/A | -27 | N/A | -18 | N/A |
| 12/31/2018 | N/A | -26 | N/A | -18 | N/A |
| 9/30/2018 | N/A | -22 | N/A | -16 | N/A |
| 12/31/2017 | N/A | -13 | N/A | -8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TRVI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TRVI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TRVI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TRVI is forecast to have no revenue next year.
High Growth Revenue: TRVI is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TRVI's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/06 05:58 |
| End of Day Share Price | 2026/01/06 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Trevi Therapeutics, Inc. is covered by 15 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | BMO Capital Markets Equity Research |
| William Wood | B. Riley Securities, Inc. |
| Mayank Mamtani | B. Riley Securities, Inc. |